Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 12.8% – Here’s Why

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s stock price shot up 12.8% on Wednesday . The stock traded as high as $5.99 and last traded at $5.99. 75,815 shares changed hands during trading, a decline of 49% from the average session volume of 148,629 shares. The stock had previously closed at $5.31.

Armata Pharmaceuticals Price Performance

The firm has a 50-day moving average price of $5.11 and a two-hundred day moving average price of $3.32. The firm has a market capitalization of $217.62 million, a P/E ratio of -3.70 and a beta of 1.24.

Hedge Funds Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC bought a new position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company’s stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.